AbbVie (ABBV) Advances Parkinson's Treatment With Tavapadon NDA

AbbVie Inc. (NYSE:ABBV) ranks among the top picks for a retirement portfolio. The FDA received a New Drug Application from AbbVie Inc. (NYSE:ABBV) on September 26 for tavapadon, an experimental oral medication used once daily to treat Parkinson’s disease.

The application is based on data from the Phase 3 TEMPO clinical trial, which assessed tavapadon across the Parkinson’s disease spectrum. The program comprised of two trials in early Parkinson’s disease (TEMPO-1 and TEMPO-2) along with a trial (TEMPO-3) that tested tavapadon as an additional therapy to levodopa in patients with motor irregularities.

At week 26, TEMPO-1 and TEMPO-2 showed a significant increase in the Movement Disorder Society’s Unified Parkinson’s Disease Rating Scale Parts II and III combined score compared to baseline.

AbbVie Inc. (NYSE:ABBV) is a biopharmaceutical company that specializes in developing, manufacturing, and marketing therapies for complicated and chronic illnesses. Its next-generation immunology medications, Rinvoq and Skyrizi, continue to drive growth.

While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.